Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences
Summary
To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.
Official title: Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary Intervention
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2025-03-01
Completion Date
2026-12-01
Last Updated
2025-02-25
Healthy Volunteers
No
Conditions
Interventions
Xuesaitong soft capsule (main ingredient is Panax notoginseng saponins)
Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + Xuesaitong soft capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12 weeks.
placebo capsule
Routine western medicine treatment (oral drug therapy and standard percutaneous coronary intervention) + placebo capsule, 0.33g/ tablets, 2 tablets each time, twice a day. The treatment period is 12weeks.
Locations (1)
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Beijing, China